Putin jokingly suggests Russia should develop teleportationScience & Space December 09, 2:07
Russian investigators conduct searches across Russia over doping casesSport December 09, 1:52
Source: Postponing OPEC, non-OPEC meeting still option for RussiaBusiness & Economy December 09, 0:35
Sports arbitration court strips Russian boxer of 2016 Olympic silverSport December 08, 22:48
Russia, US military experts, diplomats to discuss Aleppo in Geneva on Dec. 10 - LavrovWorld December 08, 22:41
Lavrov says US voiced regret over shelling of hospital in Aleppo but somewhat hazilyRussian Politics & Diplomacy December 08, 21:48
Budget revenues from Rosneft privatization to be $11.1 bln — ministerBusiness & Economy December 08, 21:18
Lavrov, Kerry discuss militants’ withdrawal from Aleppo — Russian foreign ministryRussian Politics & Diplomacy December 08, 21:00
Lavrov: Combat actions in Aleppo suspended to take civilians out of cityRussian Politics & Diplomacy December 08, 20:56
SAN FRANCISCO, March 2, 2016 /PRNewswire/. Trianni, Inc. (TRIANNI) announces that key aspects of its human antibody mouse platform were issued a patent by the Federal Service for Intellectual Property (ROSPATENT), Ministry of Economic Development of the Russian Federation.
The ROSPATENT allowance covers a transgenic mouse with an engineered endogenous immunoglobulin locus deleted of its variable region gene segments and instead containing arrays of chimeric immunoglobulin gene segments. The chimeric gene segments consist of human immunoglobulin coding sequences and non-coding sequences based on the mouse immunoglobulin variable region locus. They thus confer the capacity to express antibody chains with human variable regions. The patent also covers the methods for generating the mouse.
"We are pleased with the addition of the Russian patent to our patent portfolio," commented Dr. Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. "This addition further strengthens TRIANNI's position in monoclonal antibody discovery platform."
About Trianni, Inc.
Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.
Zishan Haroon, MD, PhD
Chief Business Officer
Director of Marketing